Vasovist is indicated for contrast-enhanced magnetic resonance angiography for visualization of abdominal or limb vessels in patients with suspected or known vascular disease. “This approval creates more positive
C326 is an inhibitor of interleukin-6 (IL-6) and is the first in a new class of therapeutic proteins known as Avimer proteins. “We believe that C326 may positively
The Phase II Small Business Innovation Research (SBIR) grant will fund the company’s test based on detection of the HPV-E6 oncoprotein. The E6 protein has been identified as
The findings, presented at the 16th Migraine Trust International Symposium in London, suggest Trexima may address an unmet need among migraine sufferers, who frequently cite inconsistent effectiveness as
Acceptance for filing indicates recognition by the FDA that the submission is complete and warrants full review of the data needed to assess the safety and efficacy of
Methylnaltrexone could be a breakthrough treatment for the bowel condition as there are no medicines currently approved for POI. Methylnaltrexone has received Fast Track designation from the FDA.
Teva Pharmaceutical Industries will fund the costs of the collaboration and pay certain milestones and royalties to Procognia relating to the usage of the technology in the development
AnorMed licensed picoplatin to Poniard Pharmaceuticals (formerly NeoRx Corporation), in April 2004. Under the terms of the new amendment, AnorMed will receive a cash payment of $5 million
The agreement has the potential to provide new cancer drugs for the oncology market. As part of the agreement, the Institute for Cancer Therapeutics will also continue development
Sigma was the defendant in a suit brought by Enzo alleging, among other things, breach of contract and infringement of patents. Terms of the settlement were not disclosed.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.